Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-444
- Development stage
- Phase 3
- Lead developer
- AbbVie
- Modality
- Small Molecules, Peptides
- Administration
- Ophthalmic
01
Overview
ABBV-444 is an investigational ophthalmic drug developed as an artificial tear formulation for the treatment of Dry Eye Disease (DED). It contains trehalose and sodium hyaluronate, which are known to improve tear film stability and ocular surface comfort. Clinical studies have shown that ABBV-444 can provide rapid symptom relief, with onset of action observed as early as 30 seconds after administration. The drug has demonstrated significant reductions in DED symptom severity over a one-month period and was well tolerated by patients, with no reported adverse events. The precise mechanism of action remains undefined, but its efficacy is attributed to its lubricating and hydrating properties. Developed and manufactured by AbbVie.
Beyond the preview
Go deeper on ABBV-444.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-444.